Craig A Collard bought $138k of HRTX
Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/. 150,000 shares at an average of $0.92, traded Nov 16, 2023, filed Nov 17, 2023.
Score components
- +25RoleCEO
- +11Trade size$138k at market
- +10Relative to holdingsHoldings up 411%
- +8Price context72% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +66.1%, 3m +163.3%, 6m +193.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-055664, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 16, 2023 | POpen-market purchase Common Stock | +150,000 | $0.92 | $138k | 186,496 | Nov 17, 2023 |
Related signals
Other insiders at HERON THERAPEUTICS, INC. /DE/ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | HERON THERAPEUTICS, INC. /DE/ | Rubric Capital Management LP owner | $3.6M 2,387,225 shares | +9% | |
| 54Moderate | HERON THERAPEUTICS, INC. /DE/ | Adam Morgan director | $2.6M 1,766,546 shares | +25% | |
| 54Moderate | HERON THERAPEUTICS, INC. /DE/ | William P Forbes EVP, Chief Development Officer | $27k 25,000 shares | +46% | |
| 54Moderate | HERON THERAPEUTICS, INC. /DE/ | William P Forbes EVP, Chief Development Officer | $47k 50,000 shares | +1250% | |
| 61Notable | HERON THERAPEUTICS, INC. /DE/ | Ira Duarte EVP, Chief Financial Officer | $76k 85,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.